Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CNR1 | P21554 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venlafaxine SCHEMBL6126163 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL7140489 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL3644633 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL27838459 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL35154 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10616028 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL60857 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10614031 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL1560692 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL4180945 | 0.96 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3846 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294257-B1 | METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY | REGENERON PHARMA (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250320301-A1 | METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY | REGENERON PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | claimed |
| EP-4596043-A2 | A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN INCREASING BONE MASS IN A SUBJECT SUFFERING FROM METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA | Regeneron Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-12371503-B2 | Methods of treatment using a leptin receptor agonist antibody | REGENERON PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | claimed |
| EP-3773713-B1 | A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN INCREASING BONE MASS IN A SUBJECT SUFFERING FROM METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA | REGENERON PHARMA (US) | 2025-07-09 | — | — | EP | claimed |
| CN-119770536-A | Combined medicine for treating depression and application thereof | 西安远大德天药业股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025056077-A1 | SURFACE-MODIFIED OXIDE SOLID ELECTROLYTE POWDER, COMPOSITE SOLID ELECTROLYTE, AND PREPARATION METHOD THEREFOR | 有研稀土高技术有限公司 | 2025-03-20 | — | — | WO | claimed |
| CN-119619366-A | Method for measuring nitrosamine impurity content in venlafaxine hydrochloride sustained release tablet | 南通联亚药业股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119499199-A | Venlafaxine hydrochloride sustained release tablet and preparation method thereof | 天津力生制药股份有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-116354835-B | Preparation method of venlafaxine hydrochloride EP impurity H | 浙江普洛家园药业有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20020025339-A1 | Extended release formulation | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-28 | — | — | US | claimed |
| US-20020006440-A1 | Rapid-melt semi-solid compositions, methods of making same and methods of using same | CAPRICORN PHARMA, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2002002081-A1 | RAPID-MELT SEMI-SOLID COMPOSITIONS, METHODS OF MAKING SAME AND METHODS OF USING SAME | CAPRICORN PHARMA, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-20010055612-A1 | Extended release formulation | AMERICAN HOME PRODUCTS CORPORATION FIVE GIRALDA FARMS | 2001-12-27 | — | — | US | claimed |
| US-6274171-B1 | Antidepressant; Side effect reduction of nausea and vomiting | AMERICAN HOME PRODUCTS CORPORATION | 2001-08-14 | — | — | US | claimed |
| WO-2001037815-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND | ALZA CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| CN-1278165-A | Extended release formulation contg. venlafaxin | AMERICAN HOME PROD (US) | 2000-12-27 | — | — | CN | claimed |
| EP-1028718-A2 | EXTENDED RELEASE FORMULATION CONTAINING VENLAFAXIN | AMERICAN HOME FOOD PRODUCTS, INC. (US) | 2000-08-23 | — | — | EP | claimed |
| WO-1999022724-A2 | EXTENDED RELEASE FORMULATION CONTAINING VENLAFAXIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-05-14 | — | — | WO | claimed |
| EP-0797991-A1 | Extended release formulation containing venlafaxine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-01 | — | — | EP | claimed |